Coherus Oncology, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Information Our common stock has been listed on The Nasdaq Global Market under the symbol “CHRS” since November 6, 2014. Prior to that there was no public trading market for our common stock. The following table details the quarterly high and low sales prices for our common stock as reported by The Nasdaq Global Market for CHRS from January 1, 2019 through December 31, 2020. ​ ​ ​ ​ ​ ​ ​ ​ ​ Price Range ​ High Low Year ended December 31, 2020 ​ ​ ​ ​ ​ ​ 1st Quarter ​ $ 23.03 ​ $ 10.86 2nd Quarter ​ 19.72 ​ 14.12 3rd Quarter ​ 20.73 ​ 17.03 4th Quarter ​ 19.12 ​ 16.26 Year ended December 31, 2019 ​ ​ 1st Quarter ​ $ 15.62 ​ $ 8.32 2nd Quarter ​ 22.17 ​ 12.95 3rd Quarter ​ 23.91 ​ 16.16 4th Quarter ​ 22.08 ​ 15.50 ​ On February 19, 2021, the closing sale price of our common stock was $17.27. Common Stockholders As of January 31, 2021, there were approximately 29 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. Dividend Policy We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. We entered into 8.2% senior convertible notes in February 2016 and 1.5% convertible notes in April 2020, each of which preclude the Company, directly or indirectly, to declare dividends so long as any of the notes are outstanding. Stock Performance Graph The following graph shows the total stockholder’s return on an investment of $100 in cash at market close on November 6, 2014 (the first day of trading of our common stock), through December 31, 2020 for (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder return. This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our 65 Table of Contents filings under the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. Recent Sales of Unregistered Equity Securities From January 1, 2020 through December 31, 2020, there were no sales or issuances of unregistered securities that were not otherwise reported in a Form 10-Q or Form 8-K. Issuer Purchases of Equity Securities We did not repurchase any of our equity securities during the fiscal year ended December 31, 2020. ​ Item 6. Selected Financial Data Not required.